NovaBay Pharmaceuticals, Inc.  

(Public, NYSEMKT:NBY)   Watch this stock  
Find more results for NBY
+0.006 (4.31%)
Nov 25 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.13 - 0.15
52 week 0.13 - 1.05
Open 0.13
Vol / Avg. 312,694.00/465,007.00
Mkt cap 12.52M
P/E     -
Div/yield     -
EPS -0.32
Shares 87.14M
Beta 0.72
Inst. own 4%
Nov 19, 2015
Q3 2015 NovaBay Pharmaceuticals Inc Earnings Call - Webcast
Nov 19, 2015
Q3 2015 NovaBay Pharmaceuticals Inc Earnings Release
Sep 10, 2015
NovaBay Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -436.83% -1441.56%
Operating margin -445.67% -1601.33%
EBITD margin - -1579.32%
Return on average assets -249.35% -131.06%
Return on average equity -819.55% -293.21%
Employees 32 -
CDP Score - -


5980 Horton St Ste 550
EMERYVILLE, CA 94608-2045
United States - Map
+1-510-8998800 (Phone)
+1-510-2250371 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NovaBay Pharmaceuticals, Inc. (NovaBay) is a biopharmaceutical company. The Company operates through four segments: dermatology, ophthalmology, urology and wound care. The dermatology segment includes NovaBay's business around the dermatology area, including the collaboration with Galderma and their impetigo clinical trial. The dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. The ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The ophthalmology segment also includes the i-Case product which is in development phases. The urology segment includes its urinary catheter encrustation and blockage (UCBE) trials. NovaBay completed Phase II clinical study of auriclosene to reduce UCBE. The wound care segment includes the business of NeutroPhase product. Its products under development stage include Aganocide Compounds.

Officers and directors

Mark M. Sieczkarek Chairman of the Board, Interim President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Thomas J Paulson Chief Financial Officer, Treasurer, Secretary, IR Contact Officer
Age: 68
Bio & Compensation  - Reuters
Russell A. Hoon Senior Vice President - Advanced wood care
Age: 62
Bio & Compensation  - Reuters
David W. Stroman Ph.D. Senior Vice President - Ophthalmic Product Development
Age: 70
Bio & Compensation  - Reuters
Roy J. Wu Senior Vice President - Business & Corporate Development
Age: 60
Bio & Compensation  - Reuters
Xinzhou Li Director
Age: 51
Bio & Compensation  - Reuters
Massimo Radaelli Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
Paul E. Freiman Independent Director
Age: 80
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 57
Bio & Compensation  - Reuters